Glucagon Market - By Product Type (Injectable, Inhalation), Application (Hypoglycemia, Diagnostic Aid, Gastrointestinal Disorders), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Global Forecast (2024 – 2032)

Glucagon Market Size

Glucagon Market size was valued at around USD 422.6 million in 2023 and is estimated to grow at 5.9% CAGR from 2024 to 2032. Glucagon is a hormone produced by the pancreas that plays a crucial role in regulating blood sugar levels in the body. It acts in opposition to insulin - another pancreatic hormone, contributing to maintaining glucose homeostasis. In instances of low blood sugar levels, glucagon is released into the bloodstream, stimulating the liver.

This stimulation results in the conversion of stored glycogen into glucose, is then released into the bloodstream to raise blood sugar levels. This process known as glycogenolysis, is facilitated by glucagon. The increasing prevalence of diabetes serves as a substantial impetus for market growth. For instance, according to the National Institutes of Health (NIH), in 2021, an estimated 529 million individuals were affected with type 2 diabetes predominantly driving approximately 96% of diabetes cases globally. Thus, this underscores the significant demand for diabetes management and treatment solutions.

Furthermore, increasing research & development activities, growing demand for non-injectable emergency glycogen, advancements in pharmaceutical sector are the contributing factors stimulating the growth of the market.
 

Glucagon Market Trends

Advancements in the pharmaceutical sector are driving innovation and progress in the development and utilization of glucagon therapies, offering numerous advantages for patients, healthcare providers, and pharmaceutical companies alike. As the prevalence of diabetes continues to rise globally, there is an increasing demand for effective treatments to manage hypoglycemic emergencies and related conditions.
 

• Advancements in pharmaceutical technology facilitate the creation of innovative glucagon formulations, characterized by enhanced stability, bioavailability, and ease of administration. These novel drug delivery systems may encompass stable liquid formulations, alternative administration methods, or pioneering drug-device combinations like autoinjectors and microneedle patches. Such innovations aim to enhance patient convenience and foster improved treatment adherence.
   
• Personalized medicine and precision medicine dosing enables the development of customized glucagon therapies tailored to individual patient needs. Pharmacogenomic research identifies genetic variations that influence glucagon metabolism and response, allowing for targeted therapies that optimize treatment efficacy and minimize adverse reactions.
   
• Additionally, pharmaceutical advancements optimize manufacturing processes for glucagon products, leading to increased production efficiency, cost-effectiveness, and scalability. Process improvements may include the adoption of advanced manufacturing technologies, automation, and quality control measures, ensuring consistent product quality and supply chain reliability, thereby escalating the growth of the market.
   

Glucagon Market Analysis

Based on product type, the market is divided into injectable and inhalation. The injectable segment is estimated to account for USD 364.7 million by the end of 2032.
 

• Injectable glucagon has a rapid onset of action, typically within minutes of administration. This rapid response is crucial in emergency situations where immediate correction of hypoglycemia is required to prevent serious complications.
   
• It is available in compact, portable kits that can be easily carried in a purse, pocket, or first aid kit. This portability ensures that glucagon is readily accessible in case of emergency, whether at home, work, or while traveling.
   
• Further, injectable glucagon is simple to administer, making it suitable for use by patients, caregivers, and healthcare professionals alike. The administration process typically involves reconstituting the powdered glucagon with a diluent and then injecting it subcutaneously, intramuscularly, or intravenously. Thus, stimulating the growth of the segment.
   

Based on application, the glucagon market is bifurcated into hypoglycemia, diagnostic aid, gastrointestinal disorders, cardiogenic shock, and other applications. The hypoglycemia segment accounted for USD 145.1 million in 2023.

• Glucagon acts quickly to raise blood sugar levels, making it essential in situations wherein hypoglycemia is severe or in the condition where person is unconscious and unable to consume sugar orally.
   
• By raising blood sugar levels, glucagon helps counteract the symptoms of hypoglycemia includes confusion, dizziness, sweating, and in severe cases, loss of consciousness or seizures.
   
• Further, glucagon is often used as an emergency treatment for severe hypoglycemia, especially in individuals affected by diabetes and prone to experiencing episodes of dangerously low blood sugar level. Thus, such aforementioned factors are expected to augment the segmental growth.
   

Based on distribution channel, the glucagon market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is estimated to account for USD 334.3 million revenue by the end of 2032.
 

• Hospital pharmacists are highly trained professionals with expertise in medication management including storage, handling, and administration of medications such as glucagon.
   
• They stock glucagon, ensuring its readiness for emergency use. This quick access is crucial in situations requiring immediate treatment to raise blood sugar levels in patients experiencing severe hypoglycemia.
   
• Further, hospital pharmacies can prepare customized dosages or formulations of glucagon as per the specific needs of patients such as adjusting concentrations for pediatric use or preparing alternative formulations for patients with allergies or sensitivities.

U.S. glucagon market is anticipated to grow at CAGR of 5.7% during the analysis timeframe.
 

• The U.S. has a highly developed pharmaceutical industry with advanced manufacturing capabilities. This allows for the production of high-quality glucagon products meeting stringent regulatory standards.
   

• It has a significant prevalence of diabetes. For instance, The National Diabetes Statistics Report for 2022 by the Centers for Disease Control (CDC) reveals that the prevalence of diabetes has increased, reached an estimated 37.3 million cases. This accounted for 11.3% of the U.S. population. Among these cases, 28.7 million people received a diabetes diagnosis, while approximately 8.6 million individuals have diabetes but remain undiagnosed.
   

Canada is expected to experience significant expansion within the global market.
 

• Health Canada, the regulatory authority for pharmaceuticals, ensures the safety, efficacy, and quality of medications, including glucagon. This regulatory oversight provides assurance to healthcare providers and patients regarding the reliability of glucagon therapy.
   
• The rising incidence of diabetes contributes significantly to the market's notable expansion. For instance, according to Public Health Agency of Canada, Canada.ca, in 2021, approximately 9.4% of the population, equivalent to 3.7 million individuals were diagnosed with diabetes, with 10% prevalence in males and 8.7% in female.
   

The glucagon market in Germany is expected to experience significant and promising growth from 2024 to 2032.
 

• Germany boasts a sophisticated healthcare system renowned for its quality and accessibility. This system ensures that medications such as glucagon are readily available to individuals with diabetes or other conditions requiring treatment for hypoglycemia.
   
• The country is at the forefront of technological innovation in healthcare. This innovation may lead to the development of advanced formulations and delivery methods for glucagon, enhancing its efficacy and ease of use.
   

UK is anticipated to witness robust growth in the global glucagon market.
 

• The UK Medicines and Healthcare products Regulatory Agency (MHRA) oversees the regulation of pharmaceutical products. This ensures that glucagon products marketed in the UK meet high standards of safety, quality, and efficacy.
   
• The UK faces a notable burden of diabetes. For instance, data from The British Diabetic Association revealed that more than 4.3 million people in the UK were managing with diabetes, while 850,000 people have diabetes but remain to undiagnosed in 2021.
   

Japan glucagon market is anticipated to witness lucrative growth between 2024 – 2032.
 

• Japan is known for its technological innovation in healthcare including pharmaceuticals. This innovation can lead to the development of advanced formulations and delivery methods for glucagon, improving its effectiveness and ease of use.
   
• The country has a significant prevalence of diabetes. For instance, according to International Diabetes Federation, in 2021, Japan experienced a diabetes prevalence of 11.8% among its total population, equating to approximately 11,004,999 cases in adults.
   

The glucagon market in Saudi Arabia is expected to experience significant and promising growth from 2024 to 2032.
 

• Saudi Arabia provides universal healthcare coverage to its citizens and residents through the Ministry of Health (MOH) and other government agencies. This ensures equitable access to medications such as glucagon for individuals with diabetes or other medical conditions.
   
• The increasing prevalence of diabetes is evident in Saudi Arabia. For instance, according to the International Diabetes Federation, in 2021 the prevalence of diabetes among adults in the country reached 17.7%, totaling approximately 4,274,100 diagnosed cases.
   

Glucagon Market Share

The glucagon industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products and services based on different technologies is among a key market strategy. Some of the leading industry players have a notable presence in the market.
 

Glucagon Market Companies

Some of the eminent market participants operating in the glucagon industry include:

• Amgen Inc.                       
• Avalon Pharma Private Limited                          
• Bachem Holding AG                     
• Eli Lilly and Company                   
• Fresenius SE & Co. KGaA                        
• Fujifilm Holdings Corporation                            
• Novo Nordisk A/S                        
• Pfizer, Inc.                        
• Svar Life Science                         
• Taj Pharmaceuticals Ltd.                        
• Xeris Biopharma Holdings, Inc.
   

Glucagon Industry News:

• In February 2020, Fresenius Kabi launched its Glucagon Emergency Kit in the U.S., containing Glucagon for Injection 1 mg and a prefilled glass syringe with 1 mL of Sterile Water for Injection. This FDA-approved kit provided a cost-effective solution for treating severe hypoglycemic episodes in people with diabetes, enhancing the company's market presence and meeting critical medical needs.
   
• In September 2019, Xeris Pharmaceuticals, Inc. announced that it had received regulatory approval from the U.S. Food and Drug Administration (FDA) for GVOKE  (glucagon) injection. GVOKE is a ready-to-use, room-temperature stable liquid glucagon designed for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 2 years and above. This approval benefited the company by expanding its product portfolio and providing a convenient and effective treatment option for a broader range of patients experiencing severe hypoglycemia.
   

The glucagon market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Injectable
• Inhalation

Market, By Application

• Hypoglycemia
• Diagnostic aid
• Gastrointestinal disorders
• Cardiogenic shock
• Other applications

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa